Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children

Yıl: 2023 Cilt: 65 Sayı: 3 Sayfa Aralığı: 425 - 432 Metin Dili: İngilizce DOI: 10.24953/turkjped.2022.232 İndeks Tarihi: 12-07-2023

Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children

Öz:
Background. There is no specific biomarker used in the diagnosis of COVID-19 and predicting its clinical severity. This study aimed to investigate the utility of ischemia-modified albumin (IMA) in diagnosing and predicting clinical severity in children with COVID-19. Methods. Between October 2020 and March 2021, 41 cases constituted the COVID-19 group and 41 cases constituted the healthy control group. IMA levels were measured at admission (IMA-1) and 48-72 hours (IMA- 2) in the COVID-19 group. In the control group, it was measured at admission. COVID-19 clinical severity was classified as asymptomatic infection, mild, moderate, severe, or critical disease. Patients were divided into two groups (asymptomatic/mild and moderate/severe) to evaluate IMA levels in terms of clinical severity. Results. In the COVID-19 group, the mean IMA-1 level was 0.901±0.099, and the mean IMA-2 level was 0.866±0.090. The mean level of IMA-1 in the control group was 0.787±0.051. When IMA-1 levels of COVID-19 and control cases were compared, the difference was statistically significant (p<0.001). When clinical severity and laboratory data are compared, C-reactive protein, ferritin and ischemia-modified albumin ratio (IMAR) were statistically significantly higher in moderate-severe clinical cases (p=0.034, p=0.034, p=0.037 respectively). However, IMA-1 and IMA-2 levels were similar between the groups (p=0.134, p=0.922, respectively). Conclusions. To date, no study has been conducted on IMA levels in children with COVID-19. The IMA level may be a new marker for the diagnosis of COVID-19 in children. Studies with a larger number of cases are needed to predict clinical severity.
Anahtar Kelime: ischemia-modified albumin COVID-19 child diagnosis clinical severity

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Chen Z, Xu W, Ma W, et al. Clinical laboratory evaluation of COVID-19. Clin Chim Acta 2021; 519: 172-182. https://doi.org/10.1016/j.cca.2021.04.022
  • 2. Bar-Or D, Lau E, Winkler JV. A novel assay for cobaltalbumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000; 19: 311-315. https://doi.org/10.1016/s0736- 4679(00)00255-9
  • 3. Aykac K, Ozsurekci Y, Tanir Basaranoglu S, et al. Oxidant and antioxidant balance in children with bacteremia [published online ahead of print, 2020]. Minerva Pediatr. 2020. https://doi.org/10.23736/ s0026-4946.20.05748-5
  • 4. Bolatkale M, Duger M, Ülfer G, et al. A novel biochemical marker for community-acquired pneumonia: ischemia-modified albumin. Am J Emerg Med 2017; 35: 1121-1125. https://doi. org/10.1016/j.ajem.2017.03.018
  • 5. Wang IK, Chang YC, Liang CC, et al. Bacteremia in hemodialysis and peritoneal dialysis patients. Intern Med 2012; 51: 1015-1021. https://doi.org/10.2169/ internalmedicine.51.7111
  • 6. World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020: 40. Available at: https://www.who.int/emergencies/diseases/novelcoronavirus- 2019
  • 7. Ducastel M, Chenevier-Gobeaux C, Ballaa Y, et al. Oxidative stress and ınflammatory biomarkers for the prediction of severity and ICU admission in unselected patients hospitalized with COVID-19. Int J Mol Sci 2021; 22: 7462. https://doi.org/10.3390/ ijms22147462
  • 8. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007; 45: 261-262. https://doi.org/10.1515/ CCLM.2007.039
  • 9. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020; 58: 1021-1028. https://doi.org/10.1515/cclm- 2020-0369
  • 10. Li H, Xiang X, Ren H, et al. Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. J Infect 2020; 80: 646-655. https://doi. org/10.1016/j.jinf.2020.03.035
  • 11. Franco-Martínez L, Tecles F, Torres-Cantero A, et al. Analytical validation of an automated assay for the measurement of adenosine deaminase (ADA) and its isoenzymes in saliva and a pilot evaluation of their changes in patients with SARS-CoV-2 infection. Clin Chem Lab Med 2021; 59: 1592-1599. https://doi. org/10.1515/cclm-2021-0324
  • 12. Ravichandran S, Banerjee U, Dr GD, et al. VB10, a new blood biomarker for differential diagnosis and recovery monitoring of acute viral and bacterial infections. EBioMedicine 2021; 67: 103352. https:// doi.org/10.1016/j.ebiom.2021.103352
  • 13. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011; 49: 177-184. https://doi.org/10.1515/CCLM.2011.037
  • 14. Yucel K, Fuat Gurbuz A. Hypoxia-inducible factor-1α and ischemia-modified albumin levels in intensive care COVID-19 patients. Horm Mol Biol Clin Investig 2022; 43: 415-420. https://doi. org/10.1515/hmbci-2022-0024
  • 15. Zendelovska D, Atanasovska E, Petrushevska M, et al. Evaluation of oxidative stress markers in hospitalized patients with moderate and severe COVID-19. Rom J Intern Med 2021; 59: 375-383. https://doi.org/10.2478/rjim-2021-0014
  • 16. Haran JP, Beaudoin FL, Suner S, Lu S. C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness. Am J Emerg Med 2013; 31: 137-144. https://doi.org/10.1016/j. ajem.2012.06.026
  • 17. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of “Ischemia modified albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004; 21: 29-34. https://doi.org/10.1136/ emj.2003.006007
  • 18. Demir H, Topkaya BC, Erbay AR, Dogan M, Yücel D. Ischaemia-modified albumin elevation after percutaneous coronary intervention reflects albumin concentration rather than ischaemia. Ann Clin Biochem 2009; 46: 327-331. https://doi.org/10.1258/ acb.2009.008238
  • 19. Karakoyun I, Ulaşoğlu C, Arslan F, et al. Oxidative imbalance in autoimmune liver disease: evaluation of oxidant-antioxidant status and ischemia-modified albumin. SDÜ Tıp Fakültesi Derg. 2021; 28: 127-135. https://doi.org/10.17343/sdutfd.738119
APA Karadag Oncel E, ELVAN TÜZ A, Ekemen Keleş Y, SAHIN A, Üstündağ G, Taşar S, Altan T, Karakoyun İ, BAŞOK B, neselioglu s, Kara-Aksay A, YILMAZ ÇIFTDOGAN D, EREL O (2023). Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. , 425 - 432. 10.24953/turkjped.2022.232
Chicago Karadag Oncel Eda,ELVAN TÜZ AYŞEGÜL,Ekemen Keleş Yıldız,SAHIN Aslıhan,Üstündağ Gülnihan,Taşar Selin,Altan Tuba Kansu,Karakoyun İnanç,BAŞOK Banu İŞBİLEN,neselioglu salim,Kara-Aksay Ahu,YILMAZ ÇIFTDOGAN DILEK,EREL Ozcan Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. (2023): 425 - 432. 10.24953/turkjped.2022.232
MLA Karadag Oncel Eda,ELVAN TÜZ AYŞEGÜL,Ekemen Keleş Yıldız,SAHIN Aslıhan,Üstündağ Gülnihan,Taşar Selin,Altan Tuba Kansu,Karakoyun İnanç,BAŞOK Banu İŞBİLEN,neselioglu salim,Kara-Aksay Ahu,YILMAZ ÇIFTDOGAN DILEK,EREL Ozcan Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. , 2023, ss.425 - 432. 10.24953/turkjped.2022.232
AMA Karadag Oncel E,ELVAN TÜZ A,Ekemen Keleş Y,SAHIN A,Üstündağ G,Taşar S,Altan T,Karakoyun İ,BAŞOK B,neselioglu s,Kara-Aksay A,YILMAZ ÇIFTDOGAN D,EREL O Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. . 2023; 425 - 432. 10.24953/turkjped.2022.232
Vancouver Karadag Oncel E,ELVAN TÜZ A,Ekemen Keleş Y,SAHIN A,Üstündağ G,Taşar S,Altan T,Karakoyun İ,BAŞOK B,neselioglu s,Kara-Aksay A,YILMAZ ÇIFTDOGAN D,EREL O Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. . 2023; 425 - 432. 10.24953/turkjped.2022.232
IEEE Karadag Oncel E,ELVAN TÜZ A,Ekemen Keleş Y,SAHIN A,Üstündağ G,Taşar S,Altan T,Karakoyun İ,BAŞOK B,neselioglu s,Kara-Aksay A,YILMAZ ÇIFTDOGAN D,EREL O "Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children." , ss.425 - 432, 2023. 10.24953/turkjped.2022.232
ISNAD Karadag Oncel, Eda vd. "Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children". (2023), 425-432. https://doi.org/10.24953/turkjped.2022.232
APA Karadag Oncel E, ELVAN TÜZ A, Ekemen Keleş Y, SAHIN A, Üstündağ G, Taşar S, Altan T, Karakoyun İ, BAŞOK B, neselioglu s, Kara-Aksay A, YILMAZ ÇIFTDOGAN D, EREL O (2023). Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. Turkish Journal of Pediatrics, 65(3), 425 - 432. 10.24953/turkjped.2022.232
Chicago Karadag Oncel Eda,ELVAN TÜZ AYŞEGÜL,Ekemen Keleş Yıldız,SAHIN Aslıhan,Üstündağ Gülnihan,Taşar Selin,Altan Tuba Kansu,Karakoyun İnanç,BAŞOK Banu İŞBİLEN,neselioglu salim,Kara-Aksay Ahu,YILMAZ ÇIFTDOGAN DILEK,EREL Ozcan Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. Turkish Journal of Pediatrics 65, no.3 (2023): 425 - 432. 10.24953/turkjped.2022.232
MLA Karadag Oncel Eda,ELVAN TÜZ AYŞEGÜL,Ekemen Keleş Yıldız,SAHIN Aslıhan,Üstündağ Gülnihan,Taşar Selin,Altan Tuba Kansu,Karakoyun İnanç,BAŞOK Banu İŞBİLEN,neselioglu salim,Kara-Aksay Ahu,YILMAZ ÇIFTDOGAN DILEK,EREL Ozcan Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. Turkish Journal of Pediatrics, vol.65, no.3, 2023, ss.425 - 432. 10.24953/turkjped.2022.232
AMA Karadag Oncel E,ELVAN TÜZ A,Ekemen Keleş Y,SAHIN A,Üstündağ G,Taşar S,Altan T,Karakoyun İ,BAŞOK B,neselioglu s,Kara-Aksay A,YILMAZ ÇIFTDOGAN D,EREL O Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. Turkish Journal of Pediatrics. 2023; 65(3): 425 - 432. 10.24953/turkjped.2022.232
Vancouver Karadag Oncel E,ELVAN TÜZ A,Ekemen Keleş Y,SAHIN A,Üstündağ G,Taşar S,Altan T,Karakoyun İ,BAŞOK B,neselioglu s,Kara-Aksay A,YILMAZ ÇIFTDOGAN D,EREL O Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children. Turkish Journal of Pediatrics. 2023; 65(3): 425 - 432. 10.24953/turkjped.2022.232
IEEE Karadag Oncel E,ELVAN TÜZ A,Ekemen Keleş Y,SAHIN A,Üstündağ G,Taşar S,Altan T,Karakoyun İ,BAŞOK B,neselioglu s,Kara-Aksay A,YILMAZ ÇIFTDOGAN D,EREL O "Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children." Turkish Journal of Pediatrics, 65, ss.425 - 432, 2023. 10.24953/turkjped.2022.232
ISNAD Karadag Oncel, Eda vd. "Evaluation of ischemia-modified albumin in the diagnosis and the clinical severity of COVID-19 in children". Turkish Journal of Pediatrics 65/3 (2023), 425-432. https://doi.org/10.24953/turkjped.2022.232